Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

Inclusion criteria

• Males or females aged between 18 and 65 years (inclusive)
• Able to give signed informed consent
• BMI 27-45 kg/m2, inclusive
• Eligible male and female subjects must agree not to participate in a conception process.
• Considered to be in stable health in the opinion of the Investigator.

Exclusion criteria

• Prior participation in any study of lorcaserin.
• Clinically significant new illness in the 1 month before screening
• Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol
• History of any of the following cardiovascular conditions:

• Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG), CVA, TIA or RIND within 6 months of screening;
• Cardiac arrhythmia requiring medical or surgical treatment within 6 months of screening
• Unstable angina
• History of pulmonary artery hypertension
• Positive result of HIV, hepatitis B or hepatitis C screens
• Malignancy within 2 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins)
• Initiation of a new prescription medication within 1 month prior to screening.
• Recent history (within 2 years prior to the screening visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening.
• Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to screening
• Use of SSRIs,SNRIs, and other medications must meet the washout period.